Cochrane · systematic review · CD010307
Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma
Kyrgidis, A, Tzellos, T, Mocellin, S, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 7 · 100%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
SLNB versus Observation for localized primary cutaneous melanoma
Population: patients with localised primary cutaneous melanoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall Survival Intention‐to‐treat Death from any cause during the study SLNB vs Observation | HR 0.99 [0.82, 1.19] | 1 study · 1661 participants | Low Downgraded: risk of bias |
Surgical Morbidity (Within 30 d) Related to the Regional Nodal Basin in Patients Assigned to the 2 Treatment Arms of MSLT‐I Any complication in the dissected basin, regional or systemic related to the surgical treatment in the regional nodal basin SLNB vs Observation | RR 14.36 [6.74, 30.59] | 1 study · 1735 participants | Low Downgraded: risk of bias |
Surgical Morbidity (Within 30 d) Related to Wide Excision of the Primary Site in Patients Assigned to the 2 Treatment Arms of MSLT‐I Any Surgical Complication related to the wide excision site SLNB vs Observation | RR 1.11 [0.9, 1.37] | 1 study · 1735 participants | Low Downgraded: risk of bias |
Disease‐specific Survival Death from melanoma SLNB vs Observation | HR 0.92 [0.74, 1.14] | 1 study · 1661 participants | Low Downgraded: risk of bias |
Disease‐free Survival First pathologically confirmed recurrence SLNB vs Observation | HR 0.75 [0.63, 0.89] | 1 study · 1661 participants | Low Downgraded: risk of bias |
Rate of pathologically confirmed locoregional recurrence following SLNB and curative CLND First pathologically confirmed local and/or regional recurrence SLNB vs Observation | RR 0.56 [0.45, 0.69] | 1 study · 1661 participants | Low Downgraded: risk of bias |
Rate of development of distant metastases following SLNB and curative CLND First pathologically confirmed distant metastasis SLNB vs Observation | RR 1.33 [1.03, 1.72] | 1 study · 1661 participants | Low Downgraded: risk of bias |